HISTOGENICS CORPORATION (NASDAQ:HSGX) Files An 8-K Results of Operations and Financial Condition

Item2.02.

On May11, 2017, Histogenics Corporation (Histogenics) issued a
press release and is holding a conference call regarding its
results of operations and financial condition for the quarter
ended March31, 2017. The press release is furnished as
Exhibit99.1 to this Current Report on Form8-K and is incorporated
by reference herein.

Various statements to be made during the conference call are
forward-looking statements under the securities laws. Words such
as, but not limited to, anticipate, believe, can, could, expect,
estimate, design, goal, intend, may, might, objective, plan,
predict, project, target, likely, should, will, and would, or the
negative of these terms and similar expressions or words,
identify forward-looking statements. Forward-looking statements
are based upon current expectations that involve risks, changes
in circumstances, assumptions and uncertainties.

Important factors that could cause actual results to differ
materially from those reflected in Histogenics forward-looking
statements include, among others: the timing and success of
Histogenics NeoCart Phase 3 clinical trial; possible delays in
enrolling the NeoCart Phase 3 clinical trial; the ability to
obtain and maintain regulatory approval of NeoCart or any product
candidates, and the labeling for any approved products; the
scope, progress, expansion, and costs of developing and
commercializing Histogenics product candidates; the ability to
obtain and maintain regulatory approval regarding the
comparability of critical NeoCart raw materials; the size and
growth of the potential markets for Histogenics product
candidates and the ability to serve those markets; Histogenics
expectations regarding its expenses and revenue; the sufficiency
of Histogenics cash resources and the availability of additional
financing on commercially reasonable terms; the early stage of
development of the technologies on which Histogenics channel
partnering agreement with Intrexon Corporation is based; the
additional expenses that Histogenics will incur in connection
with its exclusive channel collaboration agreement with Intrexon
Corporation and other factors that are described in the Risk
Factors and Managements Discussion and Analysis of Financial
Condition and Results of Operations sections of Histogenics
Annual Report on Form 10-K for the year ended December31, 2016,
which is on file with the U.S. Securities and Exchange Commission
(SEC) and available on the SECs website at www.sec.gov.
Additional factors may be set forth in those sections of
Histogenics Quarterly Report on Form 10-Q for the quarter ended
March31, 2017, to be filed with the SEC in the second quarter of
2017. In addition to the risks described above and in Histogenics
annual report on Form 10-K and quarterly reports on Form10-Q,
current reports on Form8-K and other filings with the SEC, other
unknown or unpredictable factors also could affect Histogenics
results.

There can be no assurance that the actual results or developments
anticipated by Histogenics will be realized or, even if
substantially realized, that they will have the expected
consequences to, or effects on, Histogenics. Therefore, no
assurance can be given that the outcomes stated in such
forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to
Histogenics or any person acting on its behalf are expressly
qualified in their entirety by the cautionary statements
contained or referred to herein. Histogenics cautions investors
not to rely too heavily on the forward-looking statements
Histogenics makes or that are made on its behalf. The information
conveyed on the conference call will be provided only as of the
date of the call, and Histogenics undertakes no obligation, and
specifically declines any obligation, to update or revise
publicly any forward-looking statements made during the call
after the date thereof, whether as a result of new information,
future events or otherwise.

The information in Item2.02 of this Current Report on Form8-K and
the Exhibit attached hereto shall not be deemed filed for
purposes of Section18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act) or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by
specific reference in such a filing.

About HISTOGENICS CORPORATION (NASDAQ:HSGX)

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. NeoCart is a cartilage-like implant created using a patient’s own cartilage cells through a series of tissue engineering processes. The patient’s cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Company’s Tissue Engineering Processor (TEP). The Company has operations in the United States and Israel.

HISTOGENICS CORPORATION (NASDAQ:HSGX) Recent Trading Information

HISTOGENICS CORPORATION (NASDAQ:HSGX) closed its last trading session down -0.02 at 1.68 with 7,741 shares trading hands.